Search

Your search keyword '"Usardi, P."' showing total 49 results
Start Over Author "Usardi, P."
49 results on '"Usardi, P."'

2. Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement

Author

Mantovani, Giovanna, Bastepe, Murat, Monk, David, de Sanctis, Luisa, Thiele, Susanne, Usardi, Alessia, Ahmed, S. Faisal, Bufo, Roberto, Choplin, Timothée, De Filippo, Gianpaolo, Devernois, Guillemette, Eggermann, Thomas, Elli, Francesca M., Freson, Kathleen, García Ramirez, Aurora, Germain-Lee, Emily L., Groussin, Lionel, Hamdy, Neveen, Hanna, Patrick, Hiort, Olaf, Jüppner, Harald, Kamenický, Peter, Knight, Nina, Kottler, Marie-Laure, Le Norcy, Elvire, Lecumberri, Beatriz, Levine, Michael A., Mäkitie, Outi, Martin, Regina, Martos-Moreno, Gabriel Ángel, Minagawa, Masanori, Murray, Philip, Pereda, Arrate, Pignolo, Robert, Rejnmark, Lars, Rodado, Rebecca, Rothenbuhler, Anya, Saraff, Vrinda, Shoemaker, Ashley H., Shore, Eileen M., Silve, Caroline, Turan, Serap, Woods, Philip, Zillikens, M. Carola, Perez de Nanclares, Guiomar, and Linglart, Agnès

Published
2018
Full Text
View/download PDF

8. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease

Author

Cassinotti, A., Annaloro, C., Ardizzone, S., Onida, F., Della Volpe, A., Clerici, M., Usardi, P., Greco, S., Maconi, G., Porro, G.. Bianchi, and Deliliers, G. Lambertenghi

Subjects
Autografts -- Methods, Autografts -- Research, CD4 lymphocytes -- Identification and classification, CD4 lymphocytes -- Research, Crohn's disease -- Care and treatment, Hematopoietic stem cells -- Transplantation, Hematopoietic stem cells -- Usage, Hematopoietic stem cells -- Research, Health
Published
2008

16. Reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation in advanced mycosis fungoides and Sezary syndrome

Author

Onida, F., Saporiti, G., Berti, E., Della Volpe, A., Annaloro, C., Usardi, P., Tagliaferri, E., CLAUDIA VENER, Vezzoli, P., Rambaldi, A., Bruno, B., Deliliers, G. Lambertenghi, Onida, F, Saporiti, G, Berti, E, Della Volpe, A, Annaloro, C, Usardi, P, Tagliaferri, E, Vener, C, Vezzoli, P, Rambaldi, A, Bruno, B, and Deliliers, G

Subjects
MED/15 - MALATTIE DEL SANGUE, MED/35 - MALATTIE CUTANEE E VENEREE, mycosis fungoides, Sézary syndrome, bone marrow transplant
Published
2007

19. Abstracts

Author

Van den Brink, F. G., Vaccari, Andrea, Cugurra, Franco, Mazzanti, L., Crema, A., Frigo, G. M., Del Tacca, M., Lecchini, S., Beani, L., Bianchi, C., Gandini, A., Lualdi, P., Della Bella, D., Rossini, L., Sardi, A., Baldoli, E., Caravaggi, A. M., Kyncl, J., Mauz, G., Kreye, V. A. W., Tubaro, E., Bulgini, M. J., Biagi, G. L., Barbaro, A. M., Guerra, M. C., Hümpel, J. -E., Zetler, G., Stern, P., del Bianco, P. L., Fanciullacci, M., Franchi, G., Sicuteri, F., Rovati, A. L., Casula, P. L., Meldolesi, J., Angelucci, L., Linari, G., Soldani, G., Pacini, S., de Pascale, V., Mantovani, P., Fregnan, G. B., GlÄsser, A. H., Jahrreiss, R., Habermann, E., Breithaupt, H., Rübsamen, K., Walsch, P., Lankisch, P. G., Vogt, W., Rudinger, J., Krejčí, I., Pliška, V., Poláček, I., Möhring, J., Brekner, Hanna, Schömig, A., Möhring, BÄrbel, Philippu, A., Przuntek, H., Pecile, A., Felici, M., Müller, E. E., Muller, E. E., Cocchi, D., Scapagnini, U., van Look, G. R., Moberg, G. P., Preziosi, P., Ganong, W. F., Fraschini, F., Vargiu, L., Spano, P. F., Marquardt, H., Zedeck, M. S., Sternberg, S. S., Fleisher, M., Hamilton, L. D., Classen, H. -G., Marquardt, P., SpÄth, M., Schumacher, K. -A., Bernauer, W., Hahn, F., Wissler, J., Nimptsch, P., Filipowski, P., Gjuriš, V., Wolf, D., Moroni, F., Buiatti, E., Mannaioni, P. F., Periti, P., Lorenz, W., Schauer, A., Reimann, H. J., Guidotti, A., Meyer, R., Doenicke, A., Schmal, A., Hutzel, M., Werle, E., Bertaccini, G., Impicciatore, M., Mossini, F., Frontini, E., Giani, G., Nicolin, A., Olivani, P., Dietmann, K., Schieck, A., Kornalik, F., Chiarra, A., Piccinini, F., Villani, F., Caspary, W. F., Nell, G., Forth, W., Overhoff, H., Pfleger, K., Rummel, W., Agsten, M., Voth, D., Possner, R., Förschler, M. -L., KÄvenheim, W., Kurz, H., Wirth, K., Bodem, G., Dengler, H. J., Rietbrock, N., Plato, H. v., Bergmann, K. v., Abshagen, U., Kewitz, H., Hengstmann, J. H., Konen, W., Konen, C., Backmann, H., Haschemian, A., Kemper, F., Morgenroth, K., Winterhoff, H., Mascherpa, P., Strauer, B. E., Westberg, C., Tauchert, M., Juhran, W., Ledda, F., Giotti, A., Turnheim, K., Stühlinger, W., Kraupp, O., Trendelenburg, U., Haeusler, G., Brandt, W., Reiter, M., Nakamura, J., Gerold, M., Thoenen, H., Boksay, I., Bollmann, V., Kukovetz, W. R., Klein, W. W., Pöch, G., Lüdtke, A. H., Braga, P. C., Ferri, S., Magnoni, V., Romano, A., Bartsch, W., Heinz, N., Furlanello, F., Ferrari, M., Sava, C., Maragno, I., Bergamaschi, M., Fuccella, L. M., Mandelli, V., Tommasini, R., Turba, C., Usardi, M., Lehr, E., Gesmundo, F., Susanna, A., Paroli, E., Carpi, A., Cartoni, C., Del Basso, P., Giardini, V., Marmo, E., Brogi, M., Bossa, R., Fioroni, G., Galatulas, I., Pomarelli, P., Henderson, P. Th., Remmer, H., Casals, J., Petruch, F., Schüppel, R., Forti, G. Cantelli, Fracasso, M. E., Berti, T., Maccari, M., Gatti, M. T., Losert, W., Kraaz, W., Jahn, P., Rilke, A., Cascio, G., Mantia, G., Leone, F., Datz, B., Vetter, J., Brade, W., Schönhöfer, P. S., Skidmore, I. F., Bourne, H. R., Vapaatalo, H., Bieck, P., Westermann, E., Stork, H., Schmidt, F. H., Riemenschneider, H., Willig, F., May, B., Leinweber, W., Poser, W., Panten, U., Hasselblatt, A., Klissiunis, N., Mykoniatis, M., Lengsfeld, H., Gey, K. F., Bianchini, P., Mantovani, V., LoMarco, E., Bufalina, L., Guidi, G., Osima, B., Casetta, R., Casarini, A., Mann, E., Pepeu, G., Ruffi, A., Mulas, A., Pleul, O., Lipparini, F., Loizzo, A., de Carolis, Scotti, Marino, A., Girone, E., Battista, O., de Marino, V., Florio, V., Longo, V. G., Gogolák, G., Stumpf, Ch., Pavan, P., Dross, K., Bianchi, A., Caprio, F., Kuschinsky, K., Di Carlo, R., Mandel, P., Di Rosa, M., Willoughby, D. A., Sorrentino, L., Capasso, F., Sandow, J., Alpermann, H., Metzger, H., Vogel, H. G., Velo, G. P., Capelli, A., Martinelli, G., Bertoni, F., Karzel, K., Peters, H. D., Hack, G., Fleming, K., Kazda, S., Lamprecht, F., Miksche, L., Orth, H., Philippi, A., Schmidt, D., Schneider, D., Soell, G., Taugner, R., Hammersen, G., Rosenthal, J., Fülgraff, G., Meiforth, A., Sudhoff, D., Zimmermann, E., Knebel, L., Barzaghi, F., Riva, M., Mantegazza, P., Chiesara, E., Edwards, K. D. G., Morini, M., Bilone, F., Morini, M., Ortolani, L., de Barbieri, A., Bertelli, A., Cerrati, A., Bizzi, A., Codegoni, A. M., Medea, A., Tacconi, M. T., Garattini, S., Bonaccorsi, A., Cotillo, P., and Babulova, A.

Published
1971
Full Text
View/download PDF

24. Autologous stem cell transplantation in Crohn's disease

Author

Annaloro, C., Onida, F., Usardi, P., Della Volpe, A., Cassinotti, A., Bianchi Porro, G., and Lambertenghi Deliliers, G.

Subjects
Settore MED/12 - Gastroenterologia, Settore MED/15 - Malattie del Sangue
Published
2007

31. Reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation in advanced mycosis fungoides and Sezary syndrome

Author

Onida, F, Saporiti, G, Berti, E, Della Volpe, A, Annaloro, C, Usardi, P, Tagliaferri, E, Vener, C, Vezzoli, P, Rambaldi, A, Bruno, B, Deliliers, G, Deliliers, GL, BERTI, EMILIO, Onida, F, Saporiti, G, Berti, E, Della Volpe, A, Annaloro, C, Usardi, P, Tagliaferri, E, Vener, C, Vezzoli, P, Rambaldi, A, Bruno, B, Deliliers, G, Deliliers, GL, and BERTI, EMILIO

Published
2007

32. Progressive Development of PTH Resistance in Patients With Inactivating Mutations on the Maternal Allele of GNAS.

Author

Usardi, Alessia, Mamoune, Asmaa, Nattes, Elodie, Carel, Jean-Claude, Rothenbuhler, Anya, and Linglart, Agnès

Abstract

Parathormone (PTH) resistance is characterized by hypocalcaemia, hyperphosphatemia, and elevated PTH in the absence of vitamin D deficiency. Pseudohypoparathyroidism type 1A [PHP1A, or inactivating parathormone (PTH)/PTHrp signaling disorder 2, according to the new classification (iPPSD2)], is caused by mutations in the maternal GNAS allele.

Published
2017
Full Text
View/download PDF

33. P116 - Autologous haematopoietic stem cell transplantation for refractory Crohn's disease: updating the Milan experience without CD34+ cell selection

Author

Cassinotti, A., primary, Ardizzone, S., additional, Onida, F., additional, Annaloro, C., additional, Della Volpe, A., additional, Tagliaferri, E., additional, Olivares, C., additional, Usardi, P., additional, Sampietro, G., additional, Foschi, D., additional, Fociani, P., additional, Trabattoni, D., additional, Clerici, M., additional, Lambertenghi Deliliers, G., additional, and Bianchi Porro, G., additional

Published
2009
Full Text
View/download PDF

39. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease.

Author

Cassinotti, A., Annaloro, C., Ardizzone, S., Onida, F., Della Volpe, A., Clerici, M., Usardi, P., Greco, S., Maconi, G., Bianchi Porro, G., and Lambertenghi Deliliers, G.

Subjects
HEMATOPOIETIC stem cell transplantation, ANTIGENS, CROHN'S disease, RANDOMIZED controlled trials, TOXICITY testing, HEMATOLOGY
Abstract

Objectives: Autologous haematopoietic stem cell transplantation (HSCT) with CD34+ cell selection has recently been used in the treatment of refractory Crohn's disease, showing good safety and promising efficacy. We investigated the safety and efficacy of HSCT with unselected peripheral blood stem cells (PBSCs) in moderate-severe refractory Crohn's disease. Patients: Four patients (three male, one female; age range 26-45 years) with active moderate-severe Crohn's disease (median Crohn's Disease Activity Index (CDAI) 319, range 272-345), refractory or intolerant to multiple drugs including infliximab, were enrolled. Interventions: Unselected PBSCs were collected after mobilisation with cyclophosphamide (CTX( 1.5 g/m2 and granulocyte-colony stimulating factor (G-CSF) 10 úg/kg. The conditioning regimen included CTX 50 mg/kg on days —5 to —2 and rabbit anti-thymocyte globulin (ATG) 2.5 mg/kg on days —4 to —2. Main outcome measures: Primary endpoints were toxicity and clinical remission (CDAI<150) at 3 months. Secondary endpoints were clinical and endoscopic response at 3 months and toxicity, clinical and endoscopic remission at 12 months. Results: No improvement or slight deterioration was observed following mobilisation (median CDAI 339, range 258-404). At the third month, the primary endpoint of clinical remission was achieved in all patients, with a median CDAI of 91 (range 56-102), and complete endoscopic remission was achieved in 2/3 patients. After a median follow-up of 16.5 months, ¾ patients maintained both clinical and endoscopic remission, despite withdrawal of all drugs, and complete fistula closure was observed in all affected patients. No deaths or life-threatening infection occurred. Unexpected adverse events included a perianal abscess after mobilisation in one patient, pleural and pericardial effusions in another and BK virus-related macrohaematuria in another, all rapidly resolved with conservative treatment. Conclusion: Autologous HSCT with unselected PBSC appears to be safe and can induce and maintain remission in previously refractory Crohn's disease patients. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

42. Inactivating PTH/PTHrP Signalling Disorder (iPPSD), une nouvelle proposition de classification pour les pseudohypoparathyroïdies par le réseau européen EuroPHP

Author

Thiele, S., Mantovani, G., Barlier, A., De Sanctis, L., Freson, K., Garin, I., Hanna, P., Lecumberri, B., Pereda, A., Saraff, V., Silve, C., Turan, S., Usardi, A., De Nanclares, G. Perez, and Linglart, A.

Abstract

Les pathologies qui se manifestent par une résistance à l’action de la parathormone sont appelées pseudohypoparathyroïdies (PHP). Ce terme désigne un groupe de maladies rares dont les causes sont hétérogènes, génétiques ou épigénétiques. La classification actuelle de ces pathologies repose sur la présence de signes cliniques comme la brachydactylie, l’obésité et la petite taille (l’ostéodystrophie d’Albright), sur l’absence de réponse à la PTH endogène et exogène, et sur la mesure de l’activité biologique de la protéine G. Cependant, cette classification exclue les pathologies telles que l’acrodysostose ou l’hétéroplasie osseuse progressive, de même que les bases (epi)génétiques des différents sous-types de PHP. Le réseau EuroPHP a entrepris de proposer une nouvelle classification qui englobe toutes les pathologies caractérisées par une anomalie de la voie de signalisation PTH/PTHrP.

Published
2016
Full Text
View/download PDF

43. Développement progressif de la résistance à la PTH chez les patients avec une mutation maternelle, inactivatrice de GNAS

Author

Usardi, A., Mamoune, A., Rothenbuhler, A., and Linglart, A.

Abstract

La résistance à la parathormone (PTH) est caractérisée par une hypocalcémie, une hyperphosphatémie et une PTH élevée. Dans 70–80 % des cas, elle est due à une mutation sur l’allèle maternel du gène GNAS, ou pseudohypoparathyroïdie de type 1A (PHP1A). L’objectif de cette étude est de suivre le développement de la résistance à la PTH dans une cohorte de patients PHP1A.

Published
2016
Full Text
View/download PDF

48. Increased Incidence of Metabolic Syndrome after Hematopoietic Stem Cell Transplantation.

Author

Deliliers, Giorgio Lambertenghi, Airaghi, Lorena, Usardi, Patrizia, Orsatti, Alessandra, Baldini, Marina, Giunta, Valeria, Vener, Claudia, and Annaloro, Claudio

Abstract

Metabolic syndrome (MS), formerly known as X-syndrome, is a clinical and laboratory entity involving obesity, hypertension, and borderline fasting glucose, high triglyceride and low HDL cholesterol levels, that is considered to be a counterpart of insulin resistance with overweight playing a key role; increased insulin, leptin, adiponectin and resistin levels link its various features and some common flanking findings such as hypercholesterolemia, hyperuricemia and hyperferritinemia. Clinical and laboratory data reminiscent of metabolic syndrome are commonly observed after hematopoietic stem cell transplantation (HSCT). We evaluated the body mass index (BMI), routine lipid and glucidic markers, and common endocrinologic parameters in 37 HSCT recipients (19 males; median age 45 years, range 26–60; 22 autologous, 15 allogeneic) whose continuous CR lasted at least five years; insulin (baseline and after an oral glucose test), leptin, resistin, TNF-alpha and adiponectin levels were also detemined. Diabetic HSCT recipients were excluded. The control group consisted of 23 healthy volunteers of comparable age and sex without a family history of diabetes. In comparison with the controls, the HSCT recipients had significantly increased levels of TNF (median 10.05 vs 9.3 pg/mL, p=0.034), insulin (13.6 vs 10.1 mIU/mL, p=0.029) and leptin (13.71 vs 3.69 ng/mL, p= 0.02); there were no significant differences in adiponectin and resistin levels, BMI or the other considered parameters. In comparison with the other HSCT recipients, the 16 patients with higher baseline insulin levels (>15 mIU/mL) had significantly higher leptin levels (median 23.665 vs 8.3, p<0.001), and also different total cholesterol (231 vs 202 mg/dL, p<0.01), HDL-cholesterol (58 vs 68 mg/dL, p<0.01), triglyceride (150 vs 92 mg/dL, p<0.01) and ferritin levels (635 vs 491 ng/mL, p<0.01). This preliminary investigation show an increased prevalence of MS findings in HSCT recipients, and a relationship between baseline insulin levels and some common laboratory features of MS. Unlike in spontaneously occurring cases, obesity does not seem to play a primary role; furthermore, BMI and adiponectin were not significantly increased. However, the significant increase in TNF (another inducer of insulin resistance) suggests a possible pathogenetic sequence of post-HSCT MS linking TNF, insulin and leptin. The association between MS and the development of cardiovascular diseases is well known, but HSCT may, in alternative ways, induce a long-term metabolic derangement that affects the life expectancy of patients already cured of their baseline neoplastic disease.

Published
2005
Full Text
View/download PDF

49. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.

Author

Radaelli F, Onida F, Rossi FG, Zilioli VR, Colombi M, Usardi P, Calori R, and Zanella A

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Alkylating Agents administration & dosage, Busulfan administration & dosage, Busulfan adverse effects, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hydroxyurea administration & dosage, Male, Melphalan administration & dosage, Melphalan adverse effects, Middle Aged, Retrospective Studies, Thrombocythemia, Essential complications, Young Adult, Alkylating Agents adverse effects, Hematologic Neoplasms chemically induced, Hydroxyurea adverse effects, Neoplasms, Second Primary chemically induced, Thrombocythemia, Essential drug therapy
Abstract

Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by an indolent clinical course, with a median survival exceeding 20 years. A minority of patients undergo thrombohemorrhagic complications, which might be prevented by cytoreductive treatment in high risk categories. Alkylating agents (ALK) have been demonstrated to increase the risk of acute leukemia and myelodysplastic syndromes in patients with myeloproliferative disorders, whereas the potential oncogenicity of hydroxyurea (HU) remains a matter of debate. In this study, we retrospectively investigated long-term development of hematological and non-hematological second malignancies in 331 patients with ET, analyzing possible associations with chemotherapy treatments. Median follow-up was 108 months. Of the 194 patients who were treated with chemotherapy, 116 (60%) received only HU, 38 (19.5%) only ALK (busulfan or melphalan) and 40 (20.5%) ALK followed by HU. After a median time of 87 months from the diagnosis of ET, 43 patients developed a second malignancy, hematological in 15 and non-hematological in 28, for an overall cumulative incidence of 13%. According to the type of treatment, second malignancies were documented in 11.2% of patients treated with only HU, in 26.3% of patients who received only ALK, and in 25% of those treated with ALK followed by HU. Ten cases (7.3%) were recorded among the 137 patients who did not receive any treatment. Our analysis revealed a significant association between treatment with alkylating agents and an increased risk of developing second hematological malignancies, whereas no such association was detected with regard to treatment with hydroxyurea single agent in our ET population. In addition, different treatment strategies did not affect the risk of developing second solid cancers.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results